'PY2' |
'DPH' |
'Alameda Health System' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Reported' |
'51.00%%' |
'0' |
'52.70%%' |
'1554' |
'0' |
'2690' |
'0' |
'57.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'72.70%%' |
'0' |
'73.10%%' |
'2011' |
'0' |
'2690' |
'0' |
'74.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Reported' |
'58.70%%' |
'0' |
'60.10%%' |
'210' |
'0' |
'349' |
'0' |
'60.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'51.90%%' |
'0' |
'54.40%%' |
'1481' |
'0' |
'1940' |
'0' |
'76.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'24.20%%' |
'0' |
'30.80%%' |
'322' |
'0' |
'958' |
'0' |
'33.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Reported' |
'82.80%%' |
'0' |
'79.30%%' |
'389' |
'0' |
'445' |
'0' |
'87.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'61.60%%' |
'0' |
'46.70%%' |
'170' |
'0' |
'289' |
'0' |
'58.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'78.80%%' |
'0' |
'80.00%%' |
'162' |
'0' |
'194' |
'0' |
'83.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'97.40%%' |
'0' |
'88.00%%' |
'254' |
'0' |
'266' |
'0' |
'95.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'92.70%%' |
'0' |
'90.00%%' |
'299' |
'0' |
'325' |
'0' |
'92.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'93.10%%' |
'0' |
'90.00%%' |
'190' |
'0' |
'208' |
'0' |
'91.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'93.30%%' |
'0' |
'83.00%%' |
'113' |
'0' |
'121' |
'0' |
'93.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'87.00%%' |
'0' |
'87.10%%' |
'151' |
'0' |
'165' |
'0' |
'91.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'99.40%%' |
'0' |
'90.00%%' |
'290' |
'0' |
'292' |
'0' |
'99.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'100.00%%' |
'0' |
'90.00%%' |
'385' |
'0' |
'385' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'3.70%%' |
'0' |
'25.00%%' |
'481' |
'0' |
'1186' |
'0' |
'40.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Reported' |
'83.00%%' |
'0' |
'83.70%%' |
'37' |
'0' |
'42' |
'0' |
'88.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Reported' |
'62.20%%' |
'0' |
'65.00%%' |
'64' |
'0' |
'74' |
'0' |
'86.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Reported' |
'0.00%%' |
'0' |
'10.00%%' |
'' |
'1' |
'244' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-RU5' |
'? RATE #1' |
'Reported' |
'6.10%%' |
'0' |
'10.30%%' |
'' |
'1' |
'548' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'Alameda Health System' |
'Q-RU5' |
'? RATE #2' |
'Reported' |
'6.80%%' |
'0' |
'10.30%%' |
'39' |
'0' |
'740' |
'0' |
'5.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'54.30%%' |
'0' |
'54.70%%' |
'995' |
'0' |
'1843' |
'0' |
'54.00%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Reported' |
'34.80%%' |
'0' |
'47.60%%' |
'946' |
'0' |
'1843' |
'0' |
'51.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'36.90%%' |
'0' |
'52.70%%' |
'1139' |
'0' |
'1843' |
'0' |
'61.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'52.70%%' |
'0' |
'56.50%%' |
'270' |
'0' |
'395' |
'0' |
'68.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Reported' |
'N/A' |
'0' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'0' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-PC7' |
'? 12-24 Months' |
'Reported' |
'' |
'1' |
'N/A' |
'32' |
'0' |
'37' |
'0' |
'86.50%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-PC7' |
'? 25 Months-6 Years' |
'Reported' |
'74.20%%' |
'0' |
'84.90%%' |
'699' |
'0' |
'842' |
'0' |
'83.00%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-PC7' |
'? 7-11 Years' |
'Reported' |
'76.60%%' |
'0' |
'87.60%%' |
'523' |
'0' |
'961' |
'0' |
'54.40%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-PC7' |
'? 12-19 Years' |
'Reported' |
'71.80%%' |
'0' |
'85.70%%' |
'692' |
'0' |
'1340' |
'0' |
'51.60%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Reported' |
'47.90%%' |
'0' |
'62.30%%' |
'98' |
'0' |
'141' |
'0' |
'69.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'58.10%%' |
'0' |
'46.70%%' |
'104' |
'0' |
'192' |
'0' |
'54.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'14.80%%' |
'0' |
'25.00%%' |
'43' |
'0' |
'66' |
'0' |
'65.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'29.20%%' |
'0' |
'50.00%%' |
'228' |
'0' |
'249' |
'0' |
'91.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'24.90%%' |
'0' |
'50.00%%' |
'150' |
'0' |
'211' |
'0' |
'71.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'24.40%%' |
'0' |
'50.00%%' |
'240' |
'0' |
'315' |
'0' |
'76.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'38.30%%' |
'0' |
'50.00%%' |
'210' |
'0' |
'263' |
'0' |
'79.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'40.80%%' |
'0' |
'50.00%%' |
'135' |
'0' |
'218' |
'0' |
'61.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'0.00%%' |
'0' |
'25.00%%' |
'26' |
'0' |
'96' |
'0' |
'27.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'' |
'1' |
'25.00%%' |
'378' |
'0' |
'441' |
'0' |
'85.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'40.00%%' |
'0' |
'45.00%%' |
'27' |
'0' |
'32' |
'0' |
'84.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Reported' |
'' |
'1' |
'N/A' |
'' |
'1' |
'' |
'4' |
'' |
'1' |
'0' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Reported' |
'' |
'4' |
'N/A' |
'18' |
'0' |
'' |
'4' |
'' |
'4' |
'0' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Reported' |
'' |
'1' |
'10.00%%' |
'' |
'1' |
'75' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'0' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-RU5' |
'? RATE #1' |
'Reported' |
'24.40%%' |
'0' |
'18.00%%' |
'13' |
'0' |
'' |
'4' |
'' |
'4' |
'0' |
'PY2' |
'DPH' |
'Arrowhead Regional Medical Center' |
'Q-RU5' |
'? RATE #2' |
'Reported' |
'26.30%%' |
'0' |
'18.00%%' |
'14' |
'0' |
'199' |
'0' |
'7.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'57.70%%' |
'0' |
'57.80%%' |
'2484' |
'0' |
'4261' |
'0' |
'58.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Reported' |
'55.70%%' |
'0' |
'56.90%%' |
'2641' |
'0' |
'4261' |
'0' |
'62.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'75.70%%' |
'0' |
'75.70%%' |
'3285' |
'0' |
'4261' |
'0' |
'77.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Reported' |
'53.00%%' |
'0' |
'55.60%%' |
'634' |
'0' |
'1094' |
'0' |
'58.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'99.40%%' |
'0' |
'77.60%%' |
'2209' |
'0' |
'2218' |
'0' |
'99.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'45.00%%' |
'0' |
'49.50%%' |
'164' |
'0' |
'274' |
'0' |
'59.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-PC7' |
'? 12-24 Months' |
'Reported' |
'93.40%%' |
'0' |
'93.90%%' |
'1163' |
'0' |
'1219' |
'0' |
'95.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-PC7' |
'? 25 Months-6 Years' |
'Reported' |
'83.20%%' |
'0' |
'84.90%%' |
'5241' |
'0' |
'6069' |
'0' |
'86.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-PC7' |
'? 7-11 Years' |
'Reported' |
'85.40%%' |
'0' |
'87.60%%' |
'4694' |
'0' |
'5277' |
'0' |
'89.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-PC7' |
'? 12-19 Years' |
'Reported' |
'83.30%%' |
'0' |
'85.70%%' |
'6103' |
'0' |
'6993' |
'0' |
'87.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Reported' |
'82.40%%' |
'0' |
'79.30%%' |
'970' |
'0' |
'1139' |
'0' |
'85.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'48.50%%' |
'0' |
'46.70%%' |
'423' |
'0' |
'847' |
'0' |
'49.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'76.10%%' |
'0' |
'77.50%%' |
'383' |
'0' |
'465' |
'0' |
'82.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'91.20%%' |
'0' |
'88.00%%' |
'1647' |
'0' |
'1780' |
'0' |
'92.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'76.20%%' |
'0' |
'77.60%%' |
'764' |
'0' |
'969' |
'0' |
'78.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'88.10%%' |
'0' |
'88.30%%' |
'351' |
'0' |
'383' |
'0' |
'91.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'81.30%%' |
'0' |
'81.40%%' |
'370' |
'0' |
'448' |
'0' |
'82.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'94.50%%' |
'0' |
'88.00%%' |
'477' |
'0' |
'489' |
'0' |
'97.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'96.50%%' |
'0' |
'90.00%%' |
'517' |
'0' |
'531' |
'0' |
'97.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'98.10%%' |
'0' |
'90.00%%' |
'597' |
'0' |
'617' |
'0' |
'96.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'' |
'1' |
'25.00%%' |
'101' |
'0' |
'116' |
'0' |
'87.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Reported' |
'' |
'1' |
'10.00%%' |
'' |
'1' |
'1036' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-RU5' |
'? RATE #1' |
'Reported' |
'7.20%%' |
'0' |
'10.30%%' |
'147' |
'0' |
'2200' |
'0' |
'6.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Contra Costa Regional Medical Center' |
'Q-RU5' |
'? RATE #2' |
'Reported' |
'9.60%%' |
'0' |
'10.30%%' |
'174' |
'0' |
'2200' |
'0' |
'7.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'55.00%%' |
'0' |
'55.30%%' |
'1079' |
'0' |
'1901' |
'0' |
'56.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'69.70%%' |
'0' |
'70.30%%' |
'1359' |
'0' |
'1901' |
'0' |
'71.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Reported' |
'' |
'1' |
'55.60%%' |
'23' |
'0' |
'31' |
'0' |
'74.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'67.90%%' |
'0' |
'68.80%%' |
'896' |
'0' |
'1072' |
'0' |
'83.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'25.80%%' |
'0' |
'32.20%%' |
'47' |
'0' |
'98' |
'0' |
'48.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'31.10%%' |
'0' |
'32.70%%' |
'102' |
'0' |
'282' |
'0' |
'36.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'93.50%%' |
'0' |
'90.00%%' |
'112' |
'0' |
'117' |
'0' |
'95.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'92.00%%' |
'0' |
'88.00%%' |
'262' |
'0' |
'274' |
'0' |
'95.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'88.70%%' |
'0' |
'88.90%%' |
'163' |
'0' |
'174' |
'0' |
'93.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'89.70%%' |
'0' |
'89.80%%' |
'128' |
'0' |
'133' |
'0' |
'96.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'95.40%%' |
'0' |
'83.00%%' |
'89' |
'0' |
'91' |
'0' |
'97.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'96.00%%' |
'0' |
'88.00%%' |
'88' |
'0' |
'91' |
'0' |
'96.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Reported' |
'1.7836' |
'0' |
'1.254' |
'' |
'1' |
'5.107' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'100.00%%' |
'0' |
'90.00%%' |
'1079' |
'0' |
'1079' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'100.00%%' |
'0' |
'90.00%%' |
'996' |
'0' |
'997' |
'0' |
'99.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'96.20%%' |
'0' |
'90.00%%' |
'376' |
'0' |
'412' |
'0' |
'91.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Reported' |
'96.90%%' |
'0' |
'90.00%%' |
'31' |
'0' |
'31' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Reported' |
'0.00%%' |
'0' |
'10.00%%' |
'0' |
'0' |
'109' |
'0' |
'0.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Reported' |
'100.00%%' |
'0' |
'90.00%%' |
'134' |
'0' |
'147' |
'0' |
'91.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-RU5' |
'? RATE #1' |
'Reported' |
'12.20%%' |
'0' |
'12.10%%' |
'23' |
'0' |
'470' |
'0' |
'4.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Kern Medical Center' |
'Q-RU5' |
'? RATE #2' |
'Reported' |
'11.10%%' |
'0' |
'11.10%%' |
'36' |
'0' |
'1100' |
'0' |
'3.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'52.50%%' |
'0' |
'53.10%%' |
'8117' |
'0' |
'15264' |
'0' |
'53.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Reported' |
'71.90%%' |
'0' |
'68.20%%' |
'293' |
'0' |
'411' |
'0' |
'71.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'66.10%%' |
'0' |
'67.10%%' |
'10702' |
'0' |
'15264' |
'0' |
'70.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Reported' |
'47.60%%' |
'0' |
'55.60%%' |
'1075' |
'0' |
'1520' |
'0' |
'70.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'45.70%%' |
'0' |
'48.90%%' |
'4974' |
'0' |
'7700' |
'0' |
'64.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Reported' |
'86.40%%' |
'0' |
'79.30%%' |
'267' |
'0' |
'323' |
'0' |
'82.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'55.40%%' |
'0' |
'46.70%%' |
'176' |
'0' |
'278' |
'0' |
'63.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'78.80%%' |
'0' |
'79.90%%' |
'838' |
'0' |
'971' |
'0' |
'86.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'93.20%%' |
'0' |
'88.00%%' |
'3078' |
'0' |
'3341' |
'0' |
'92.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'86.30%%' |
'0' |
'86.70%%' |
'1620' |
'0' |
'1805' |
'0' |
'89.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'85.30%%' |
'0' |
'85.80%%' |
'1127' |
'0' |
'1293' |
'0' |
'87.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'78.80%%' |
'0' |
'79.20%%' |
'605' |
'0' |
'707' |
'0' |
'85.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'89.70%%' |
'0' |
'88.00%%' |
'648' |
'0' |
'727' |
'0' |
'89.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'91.90%%' |
'0' |
'90.00%%' |
'364' |
'0' |
'377' |
'0' |
'96.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'80.80%%' |
'0' |
'81.70%%' |
'367' |
'0' |
'377' |
'0' |
'97.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'57.80%%' |
'0' |
'61.10%%' |
'317' |
'0' |
'377' |
'0' |
'84.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Reported' |
'98.10%%' |
'0' |
'90.00%%' |
'83' |
'0' |
'87' |
'0' |
'95.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Reported' |
'99.50%%' |
'0' |
'90.00%%' |
'267' |
'0' |
'267' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Reported' |
'' |
'1' |
'10.00%%' |
'' |
'1' |
'327' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-RU5' |
'? RATE #1' |
'Reported' |
'4.70%%' |
'0' |
'10.30%%' |
'97' |
'0' |
'1982' |
'0' |
'4.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Los Angeles County Health System' |
'Q-RU5' |
'? RATE #2' |
'Reported' |
'9.40%%' |
'0' |
'10.30%%' |
'296' |
'0' |
'3452' |
'0' |
'8.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'51.40%%' |
'0' |
'52.10%%' |
'945' |
'0' |
'1755' |
'0' |
'53.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'73.60%%' |
'0' |
'73.80%%' |
'1303' |
'0' |
'1755' |
'0' |
'74.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Reported' |
'65.00%%' |
'0' |
'65.80%%' |
'281' |
'0' |
'421' |
'0' |
'66.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'57.50%%' |
'0' |
'59.50%%' |
'501' |
'0' |
'823' |
'0' |
'60.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'48.90%%' |
'0' |
'53.00%%' |
'38' |
'0' |
'56' |
'0' |
'67.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'0.75' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-PC7' |
'? 12-24 Months' |
'Reported' |
'94.90%%' |
'0' |
'95.20%%' |
'1397' |
'0' |
'1465' |
'0' |
'95.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-PC7' |
'? 25 Months-6 Years' |
'Reported' |
'90.90%%' |
'0' |
'91.10%%' |
'5936' |
'0' |
'6691' |
'0' |
'88.70%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-PC7' |
'? 7-11 Years' |
'Reported' |
'89.30%%' |
'0' |
'90.00%%' |
'6105' |
'0' |
'6711' |
'0' |
'91.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-PC7' |
'? 12-19 Years' |
'Reported' |
'84.20%%' |
'0' |
'85.70%%' |
'6679' |
'0' |
'7752' |
'0' |
'86.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Reported' |
'87.90%%' |
'0' |
'79.30%%' |
'903' |
'0' |
'1048' |
'0' |
'86.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'72.90%%' |
'0' |
'46.70%%' |
'720' |
'0' |
'923' |
'0' |
'78.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'86.70%%' |
'0' |
'87.10%%' |
'121' |
'0' |
'137' |
'0' |
'88.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'80.10%%' |
'0' |
'80.90%%' |
'257' |
'0' |
'315' |
'0' |
'81.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'82.60%%' |
'0' |
'83.40%%' |
'152' |
'0' |
'182' |
'0' |
'83.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'82.30%%' |
'0' |
'83.10%%' |
'62' |
'0' |
'70' |
'0' |
'88.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'80.00%%' |
'0' |
'80.30%%' |
'37' |
'0' |
'41' |
'0' |
'90.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'68.60%%' |
'0' |
'70.50%%' |
'41' |
'0' |
'41' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'42.60%%' |
'0' |
'47.30%%' |
'473' |
'0' |
'747' |
'0' |
'63.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'64.10%%' |
'0' |
'66.70%%' |
'663' |
'0' |
'709' |
'0' |
'93.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'80.50%%' |
'0' |
'81.50%%' |
'257' |
'0' |
'291' |
'0' |
'88.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Reported' |
'' |
'1' |
'10.00%%' |
'0' |
'0' |
'85' |
'0' |
'0.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-RU4' |
'? Adjusted Percentile' |
'Reported' |
'61' |
'0' |
'57.4' |
'N/A' |
'3' |
'N/A' |
'3' |
'57' |
'0' |
'N/A' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-RU4' |
'? Outlier Status' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-RU5' |
'? RATE #1' |
'Reported' |
'7.00%%' |
'0' |
'10.30%%' |
'' |
'1' |
'176' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'Natividad Medical Center' |
'Q-RU5' |
'? RATE #2' |
'Reported' |
'9.10%%' |
'0' |
'10.30%%' |
'35' |
'0' |
'461' |
'0' |
'7.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'51.90%%' |
'0' |
'52.60%%' |
'2168' |
'0' |
'3848' |
'0' |
'56.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Reported' |
'11.40%%' |
'0' |
'47.60%%' |
'192' |
'0' |
'400' |
'0' |
'48.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'59.80%%' |
'0' |
'61.40%%' |
'2874' |
'0' |
'3848' |
'0' |
'74.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'65.40%%' |
'0' |
'66.60%%' |
'1380' |
'0' |
'1408' |
'0' |
'98.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'32.20%%' |
'0' |
'38.00%%' |
'143' |
'0' |
'343' |
'0' |
'41.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'33.70%%' |
'0' |
'35.00%%' |
'77' |
'0' |
'204' |
'0' |
'37.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'81.10%%' |
'0' |
'82.00%%' |
'131' |
'0' |
'152' |
'0' |
'86.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'85.60%%' |
'0' |
'85.90%%' |
'598' |
'0' |
'670' |
'0' |
'89.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'86.70%%' |
'0' |
'87.10%%' |
'162' |
'0' |
'184' |
'0' |
'88.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'66.40%%' |
'0' |
'68.70%%' |
'178' |
'0' |
'225' |
'0' |
'79.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'84.20%%' |
'0' |
'83.00%%' |
'152' |
'0' |
'171' |
'0' |
'88.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'81.00%%' |
'0' |
'81.70%%' |
'166' |
'0' |
'186' |
'0' |
'89.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Reported' |
'1.2177' |
'0' |
'1.1497' |
'' |
'1' |
'9.83' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'75.30%%' |
'0' |
'76.80%%' |
'210' |
'0' |
'257' |
'0' |
'81.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'10.30%%' |
'0' |
'25.00%%' |
'377' |
'0' |
'418' |
'0' |
'90.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'30.80%%' |
'0' |
'36.70%%' |
'612' |
'0' |
'882' |
'0' |
'69.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Reported' |
'84.60%%' |
'0' |
'85.20%%' |
'59' |
'0' |
'66' |
'0' |
'89.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Reported' |
'0.00%%' |
'0' |
'10.00%%' |
'0' |
'0' |
'121' |
'0' |
'0.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Reported' |
'79.50%%' |
'0' |
'80.50%%' |
'80' |
'0' |
'97' |
'0' |
'82.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Reported' |
'' |
'1' |
'29.10%%' |
'' |
'1' |
'41' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Riverside University Health System' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'61.90%%' |
'0' |
'58.50%%' |
'2082' |
'0' |
'3369' |
'0' |
'61.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Reported' |
'66.20%%' |
'0' |
'66.40%%' |
'2292' |
'0' |
'3369' |
'0' |
'68.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'75.60%%' |
'0' |
'75.60%%' |
'2586' |
'0' |
'3369' |
'0' |
'76.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'56.20%%' |
'0' |
'58.30%%' |
'1675' |
'0' |
'2867' |
'0' |
'58.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'49.40%%' |
'0' |
'53.40%%' |
'244' |
'0' |
'447' |
'0' |
'54.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Reported' |
'90.20%%' |
'0' |
'79.30%%' |
'393' |
'0' |
'451' |
'0' |
'87.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'65.40%%' |
'0' |
'46.70%%' |
'194' |
'0' |
'258' |
'0' |
'75.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'78.40%%' |
'0' |
'79.60%%' |
'272' |
'0' |
'340' |
'0' |
'80.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'93.90%%' |
'0' |
'88.00%%' |
'793' |
'0' |
'843' |
'0' |
'94.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'86.40%%' |
'0' |
'86.80%%' |
'440' |
'0' |
'499' |
'0' |
'88.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'96.10%%' |
'0' |
'90.00%%' |
'213' |
'0' |
'221' |
'0' |
'96.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'85.90%%' |
'0' |
'83.00%%' |
'359' |
'0' |
'424' |
'0' |
'84.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'94.30%%' |
'0' |
'88.00%%' |
'397' |
'0' |
'429' |
'0' |
'92.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'95.30%%' |
'0' |
'90.00%%' |
'323' |
'0' |
'337' |
'0' |
'95.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'96.80%%' |
'0' |
'90.00%%' |
'324' |
'0' |
'335' |
'0' |
'96.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'0.00%%' |
'0' |
'25.00%%' |
'354' |
'0' |
'621' |
'0' |
'57.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Reported' |
'100.00%%' |
'0' |
'90.00%%' |
'52' |
'0' |
'52' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Reported' |
'100.00%%' |
'0' |
'90.00%%' |
'90' |
'0' |
'90' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Reported' |
'' |
'1' |
'10.00%%' |
'' |
'1' |
'171' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-RU5' |
'? RATE #1' |
'Reported' |
'11.40%%' |
'0' |
'11.30%%' |
'76' |
'0' |
'872' |
'0' |
'8.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Francisco General Hospital' |
'Q-RU5' |
'? RATE #2' |
'Reported' |
'11.40%%' |
'0' |
'11.30%%' |
'90' |
'0' |
'953' |
'0' |
'9.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'50.00%%' |
'0' |
'50.90%%' |
'676' |
'0' |
'1281' |
'0' |
'52.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Reported' |
'47.30%%' |
'0' |
'49.40%%' |
'206' |
'0' |
'411' |
'0' |
'50.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'72.30%%' |
'0' |
'72.60%%' |
'872' |
'0' |
'1281' |
'0' |
'68.10%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Reported' |
'72.00%%' |
'0' |
'72.00%%' |
'24' |
'0' |
'33' |
'0' |
'72.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'44.30%%' |
'0' |
'47.60%%' |
'264' |
'0' |
'278' |
'0' |
'95.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'54.80%%' |
'0' |
'58.30%%' |
'81' |
'0' |
'137' |
'0' |
'59.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'0.25' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-PC7' |
'? 12-24 Months' |
'Reported' |
'92.30%%' |
'0' |
'93.30%%' |
'65' |
'0' |
'71' |
'0' |
'91.60%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-PC7' |
'? 25 Months-6 Years' |
'Reported' |
'70.70%%' |
'0' |
'84.90%%' |
'1332' |
'0' |
'1499' |
'0' |
'88.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-PC7' |
'? 7-11 Years' |
'Reported' |
'66.80%%' |
'0' |
'87.60%%' |
'1516' |
'0' |
'1756' |
'0' |
'86.30%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-PC7' |
'? 12-19 Years' |
'Reported' |
'67.70%%' |
'0' |
'85.70%%' |
'2388' |
'0' |
'2956' |
'0' |
'80.80%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Reported' |
'72.80%%' |
'0' |
'73.50%%' |
'280' |
'0' |
'362' |
'0' |
'77.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'52.30%%' |
'0' |
'46.70%%' |
'141' |
'0' |
'244' |
'0' |
'57.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'70.40%%' |
'0' |
'72.40%%' |
'115' |
'0' |
'147' |
'0' |
'78.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'83.20%%' |
'0' |
'83.70%%' |
'316' |
'0' |
'361' |
'0' |
'87.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'86.80%%' |
'0' |
'87.10%%' |
'184' |
'0' |
'210' |
'0' |
'87.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'83.70%%' |
'0' |
'84.30%%' |
'117' |
'0' |
'131' |
'0' |
'89.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'76.30%%' |
'0' |
'76.90%%' |
'111' |
'0' |
'117' |
'0' |
'94.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'76.30%%' |
'0' |
'77.40%%' |
'97' |
'0' |
'103' |
'0' |
'94.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Reported' |
'' |
'1' |
'1.132' |
'14' |
'0' |
'9.117' |
'0' |
'1.5356' |
'0' |
'0' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'71.60%%' |
'0' |
'73.40%%' |
'242' |
'0' |
'323' |
'0' |
'74.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'83.70%%' |
'0' |
'84.30%%' |
'229' |
'0' |
'278' |
'0' |
'82.40%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'93.80%%' |
'0' |
'90.00%%' |
'110' |
'0' |
'121' |
'0' |
'90.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Reported' |
'79.10%%' |
'0' |
'80.20%%' |
'70' |
'0' |
'72' |
'0' |
'97.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Joaquin General Hospital' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'54.90%%' |
'0' |
'55.20%%' |
'3222' |
'0' |
'5449' |
'0' |
'59.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Reported' |
'48.30%%' |
'0' |
'50.30%%' |
'3729' |
'0' |
'5449' |
'0' |
'68.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'67.50%%' |
'0' |
'68.30%%' |
'3811' |
'0' |
'5449' |
'0' |
'69.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'37.50%%' |
'0' |
'41.50%%' |
'1955' |
'0' |
'3721' |
'0' |
'52.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'9.60%%' |
'0' |
'25.00%%' |
'301' |
'0' |
'1564' |
'0' |
'19.30%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Reported' |
'75.70%%' |
'0' |
'76.10%%' |
'772' |
'0' |
'878' |
'0' |
'87.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'51.00%%' |
'0' |
'46.70%%' |
'474' |
'0' |
'974' |
'0' |
'48.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'65.40%%' |
'0' |
'67.90%%' |
'422' |
'0' |
'601' |
'0' |
'70.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'83.90%%' |
'0' |
'84.30%%' |
'1209' |
'0' |
'1400' |
'0' |
'86.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'71.80%%' |
'0' |
'73.60%%' |
'719' |
'0' |
'936' |
'0' |
'76.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'35.40%%' |
'0' |
'50.00%%' |
'371' |
'0' |
'511' |
'0' |
'72.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'0.00%%' |
'0' |
'N/A' |
'408' |
'0' |
'537' |
'0' |
'76.00%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Reported' |
'1.0675' |
'0' |
'1.0146' |
'11' |
'0' |
'13' |
'0' |
'0.8462' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'71.80%%' |
'0' |
'73.60%%' |
'1357' |
'0' |
'1817' |
'0' |
'74.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'96.10%%' |
'0' |
'90.00%%' |
'1065' |
'0' |
'1119' |
'0' |
'95.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'11.80%%' |
'0' |
'25.00%%' |
'195' |
'0' |
'609' |
'0' |
'32.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Reported' |
'85.30%%' |
'0' |
'85.80%%' |
'29' |
'0' |
'41' |
'0' |
'70.70%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Reported' |
'96.40%%' |
'0' |
'90.00%%' |
'86' |
'0' |
'90' |
'0' |
'95.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'0' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-RU4' |
'? Adjusted Percentile' |
'Reported' |
'32' |
'0' |
'31.3' |
'N/A' |
'3' |
'N/A' |
'3' |
'42' |
'0' |
'N/A' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-RU4' |
'? Outlier Status' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-RU5' |
'? RATE #1' |
'Reported' |
'6.50%%' |
'0' |
'10.30%%' |
'49' |
'0' |
'788' |
'0' |
'6.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Santa Clara Valley Medical Center' |
'Q-RU5' |
'? RATE #2' |
'Reported' |
'7.10%%' |
'0' |
'10.30%%' |
'71' |
'0' |
'932' |
'0' |
'7.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'63.10%%' |
'0' |
'58.50%%' |
'1122' |
'0' |
'1806' |
'0' |
'62.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Reported' |
'98.40%%' |
'0' |
'68.20%%' |
'1784' |
'0' |
'1806' |
'0' |
'98.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'73.80%%' |
'0' |
'74.00%%' |
'1372' |
'0' |
'1806' |
'0' |
'76.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Reported' |
'60.60%%' |
'0' |
'61.80%%' |
'120' |
'0' |
'193' |
'0' |
'62.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'48.20%%' |
'0' |
'51.10%%' |
'338' |
'0' |
'595' |
'0' |
'56.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-PC7' |
'? 12-24 Months' |
'Reported' |
'100.00%%' |
'0' |
'97.90%%' |
'278' |
'0' |
'278' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-PC7' |
'? 25 Months-6 Years' |
'Reported' |
'91.20%%' |
'0' |
'91.40%%' |
'2080' |
'0' |
'2189' |
'0' |
'95.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-PC7' |
'? 7-11 Years' |
'Reported' |
'85.40%%' |
'0' |
'87.60%%' |
'1884' |
'0' |
'1952' |
'0' |
'96.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-PC7' |
'? 12-19 Years' |
'Reported' |
'79.40%%' |
'0' |
'85.70%%' |
'2519' |
'0' |
'2629' |
'0' |
'95.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Reported' |
'67.60%%' |
'0' |
'68.80%%' |
'285' |
'0' |
'319' |
'0' |
'89.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'66.30%%' |
'0' |
'46.70%%' |
'174' |
'0' |
'253' |
'0' |
'68.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'78.90%%' |
'0' |
'80.00%%' |
'269' |
'0' |
'333' |
'0' |
'80.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'89.00%%' |
'0' |
'88.00%%' |
'635' |
'0' |
'693' |
'0' |
'91.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'88.80%%' |
'0' |
'88.90%%' |
'290' |
'0' |
'322' |
'0' |
'90.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'89.90%%' |
'0' |
'90.00%%' |
'161' |
'0' |
'177' |
'0' |
'91.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'89.80%%' |
'0' |
'83.00%%' |
'59' |
'0' |
'65' |
'0' |
'90.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'70.90%%' |
'0' |
'72.60%%' |
'77' |
'0' |
'80' |
'0' |
'96.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'96.50%%' |
'0' |
'90.00%%' |
'532' |
'0' |
'549' |
'0' |
'96.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'66.90%%' |
'0' |
'69.20%%' |
'525' |
'0' |
'529' |
'0' |
'99.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'45.60%%' |
'0' |
'50.00%%' |
'97' |
'0' |
'134' |
'0' |
'72.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Reported' |
'' |
'1' |
'10.00%%' |
'' |
'1' |
'205' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Reported' |
'80.80%%' |
'0' |
'81.70%%' |
'77' |
'0' |
'94' |
'0' |
'81.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-RU5' |
'? RATE #1' |
'Reported' |
'7.70%%' |
'0' |
'10.30%%' |
'82' |
'0' |
'1106' |
'0' |
'7.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'San Mateo Medical Center' |
'Q-RU5' |
'? RATE #2' |
'Reported' |
'8.40%%' |
'0' |
'10.30%%' |
'126' |
'0' |
'1696' |
'0' |
'7.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Reported' |
'0' |
'0' |
'N/A' |
'0' |
'0' |
'0' |
'0' |
'0.00%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'77.30%%' |
'0' |
'77.30%%' |
'87' |
'0' |
'87' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'84.50%%' |
'0' |
'85.00%%' |
'' |
'1' |
'' |
'4' |
'' |
'1' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Reported' |
'0.00%%' |
'0' |
'N/A' |
'' |
'1' |
'' |
'1' |
'' |
'1' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'' |
'1' |
'N/A' |
'' |
'1' |
'' |
'4' |
'' |
'1' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'76.50%%' |
'0' |
'77.60%%' |
'33' |
'0' |
'44' |
'0' |
'75.00%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'' |
'4' |
'N/A' |
'22' |
'0' |
'' |
'4' |
'' |
'4' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'' |
'4' |
'N/A' |
'15' |
'0' |
'' |
'4' |
'' |
'4' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'' |
'1' |
'N/A' |
'15' |
'0' |
'' |
'4' |
'' |
'4' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'' |
'1' |
'N/A' |
'19' |
'0' |
'' |
'4' |
'' |
'4' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Reported' |
'0.9128' |
'0' |
'0.8753' |
'36' |
'0' |
'35.62' |
'0' |
'1.0107' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'85.00%%' |
'0' |
'85.50%%' |
'912' |
'0' |
'1103' |
'0' |
'82.70%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'98.50%%' |
'0' |
'90.00%%' |
'1245' |
'0' |
'1303' |
'0' |
'95.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'53.20%%' |
'0' |
'56.80%%' |
'277' |
'0' |
'317' |
'0' |
'87.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Reported' |
'' |
'4' |
'N/A' |
'28' |
'0' |
'31' |
'0' |
'90.30%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Reported' |
'100.00%%' |
'0' |
'90.00%%' |
'62' |
'0' |
'65' |
'0' |
'95.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Reported' |
'' |
'4' |
'N/A' |
'0' |
'0' |
'' |
'4' |
'' |
'4' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Reported' |
'88.00%%' |
'0' |
'88.20%%' |
'117' |
'0' |
'146' |
'0' |
'80.10%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Reported' |
'12.40%%' |
'0' |
'12.20%%' |
'' |
'1' |
'82' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'0' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-RU4' |
'? Adjusted Percentile' |
'Reported' |
'45' |
'0' |
'43' |
'N/A' |
'3' |
'N/A' |
'3' |
'67' |
'0' |
'N/A' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-RU4' |
'? Outlier Status' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'PY2' |
'DPH' |
'UC Davis Medical Center' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'64.90%%' |
'0' |
'66.00%%' |
'718' |
'0' |
'1071' |
'0' |
'67.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Reported' |
'50.80%%' |
'0' |
'55.60%%' |
'59' |
'0' |
'106' |
'0' |
'55.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'53.80%%' |
'0' |
'56.10%%' |
'519' |
'0' |
'524' |
'0' |
'99.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'40.30%%' |
'0' |
'45.20%%' |
'58' |
'0' |
'112' |
'0' |
'51.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'0.5' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-PC7' |
'? 12-24 Months' |
'Reported' |
'96.60%%' |
'0' |
'96.80%%' |
'279' |
'0' |
'281' |
'0' |
'99.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-PC7' |
'? 25 Months-6 Years' |
'Reported' |
'81.00%%' |
'0' |
'84.90%%' |
'1040' |
'0' |
'1189' |
'0' |
'87.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-PC7' |
'? 7-11 Years' |
'Reported' |
'84.40%%' |
'0' |
'87.60%%' |
'488' |
'0' |
'560' |
'0' |
'87.10%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-PC7' |
'? 12-19 Years' |
'Reported' |
'82.80%%' |
'0' |
'85.70%%' |
'944' |
'0' |
'1109' |
'0' |
'85.10%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Reported' |
'71.70%%' |
'0' |
'72.50%%' |
'166' |
'0' |
'217' |
'0' |
'76.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'41.90%%' |
'0' |
'42.40%%' |
'54' |
'0' |
'121' |
'0' |
'44.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'73.10%%' |
'0' |
'74.80%%' |
'86' |
'0' |
'106' |
'0' |
'81.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'79.20%%' |
'0' |
'80.00%%' |
'222' |
'0' |
'256' |
'0' |
'86.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'83.90%%' |
'0' |
'84.50%%' |
'153' |
'0' |
'177' |
'0' |
'86.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'89.00%%' |
'0' |
'89.10%%' |
'114' |
'0' |
'125' |
'0' |
'91.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'81.10%%' |
'0' |
'81.30%%' |
'134' |
'0' |
'151' |
'0' |
'88.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'83.30%%' |
'0' |
'83.80%%' |
'142' |
'0' |
'146' |
'0' |
'97.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'56.00%%' |
'0' |
'59.40%%' |
'1452' |
'0' |
'1814' |
'0' |
'80.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'2.60%%' |
'0' |
'25.00%%' |
'582' |
'0' |
'1587' |
'0' |
'36.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Reported' |
'92.20%%' |
'0' |
'90.00%%' |
'94' |
'0' |
'94' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Reported' |
'' |
'1' |
'10.00%%' |
'' |
'1' |
'135' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Reported' |
'17.90%%' |
'0' |
'50.00%%' |
'244' |
'0' |
'421' |
'0' |
'58.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Reported' |
'' |
'1' |
'10.00%%' |
'' |
'1' |
'61' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-RU5' |
'? RATE #1' |
'Reported' |
'16.00%%' |
'0' |
'15.40%%' |
'19' |
'0' |
'180' |
'0' |
'10.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Irvine Medical Center' |
'Q-RU5' |
'? RATE #2' |
'Reported' |
'11.10%%' |
'0' |
'11.00%%' |
'37' |
'0' |
'446' |
'0' |
'8.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'56.50%%' |
'0' |
'56.70%%' |
'39' |
'0' |
'70' |
'0' |
'55.70%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Reported' |
'35.90%%' |
'0' |
'47.60%%' |
'27' |
'0' |
'70' |
'0' |
'38.60%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'73.90%%' |
'0' |
'74.10%%' |
'54' |
'0' |
'70' |
'0' |
'77.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Reported' |
'' |
'4' |
'N/A' |
'' |
'1' |
'' |
'4' |
'' |
'1' |
'0' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'69.70%%' |
'0' |
'70.50%%' |
'55' |
'0' |
'55' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'' |
'1' |
'N/A' |
'' |
'1' |
'' |
'1' |
'' |
'1' |
'0' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'0' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-PC7' |
'? 12-24 Months' |
'Reported' |
'97.00%%' |
'0' |
'97.10%%' |
'118' |
'0' |
'134' |
'0' |
'88.10%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-PC7' |
'? 25 Months-6 Years' |
'Reported' |
'84.60%%' |
'0' |
'85.40%%' |
'737' |
'0' |
'1019' |
'0' |
'72.30%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-PC7' |
'? 7-11 Years' |
'Reported' |
'88.70%%' |
'0' |
'89.40%%' |
'650' |
'0' |
'773' |
'0' |
'84.10%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-PC7' |
'? 12-19 Years' |
'Reported' |
'90.10%%' |
'0' |
'90.50%%' |
'965' |
'0' |
'1126' |
'0' |
'85.70%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Reported' |
'67.10%%' |
'0' |
'68.30%%' |
'100' |
'0' |
'147' |
'0' |
'68.00%%' |
'0' |
'0.75' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'30.30%%' |
'0' |
'31.90%%' |
'46' |
'0' |
'97' |
'0' |
'47.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'' |
'1' |
'N/A' |
'' |
'1' |
'' |
'1' |
'' |
'1' |
'0' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'68.40%%' |
'0' |
'70.40%%' |
'26' |
'0' |
'30' |
'0' |
'86.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Reported' |
'0.8464' |
'0' |
'0.8156' |
'24' |
'0' |
'30.819' |
'0' |
'0.7787' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'80.70%%' |
'0' |
'81.70%%' |
'634' |
'0' |
'741' |
'0' |
'85.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'93.30%%' |
'0' |
'90.00%%' |
'803' |
'0' |
'831' |
'0' |
'96.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'23.00%%' |
'0' |
'29.70%%' |
'783' |
'0' |
'974' |
'0' |
'80.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Reported' |
'100.00%%' |
'0' |
'90.00%%' |
'46' |
'0' |
'46' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Reported' |
'91.80%%' |
'0' |
'90.00%%' |
'280' |
'0' |
'285' |
'0' |
'98.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Reported' |
'0.00%%' |
'0' |
'10.00%%' |
'0' |
'0' |
'51' |
'0' |
'0.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-RU4' |
'? Adjusted Percentile' |
'Reported' |
'40' |
'0' |
'38.5' |
'N/A' |
'3' |
'N/A' |
'3' |
'33' |
'0' |
'N/A' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-RU4' |
'? Outlier Status' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-RU5' |
'? RATE #1' |
'Reported' |
'' |
'1' |
'18.00%%' |
'' |
'1' |
'39' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'UC Los Angeles Medical Center' |
'Q-RU5' |
'? RATE #2' |
'Reported' |
'' |
'1' |
'12.60%%' |
'' |
'1' |
'56' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'69.00%%' |
'0' |
'58.50%%' |
'259' |
'0' |
'398' |
'0' |
'65.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Reported' |
'57.60%%' |
'0' |
'58.60%%' |
'260' |
'0' |
'398' |
'0' |
'65.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'69.80%%' |
'0' |
'70.40%%' |
'297' |
'0' |
'398' |
'0' |
'74.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Reported' |
'73.00%%' |
'0' |
'72.40%%' |
'36' |
'0' |
'59' |
'0' |
'61.00%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'61.60%%' |
'0' |
'63.20%%' |
'237' |
'0' |
'271' |
'0' |
'87.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'45.50%%' |
'0' |
'49.90%%' |
'29' |
'0' |
'51' |
'0' |
'56.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'94.30%%' |
'0' |
'90.00%%' |
'94' |
'0' |
'101' |
'0' |
'93.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'84.10%%' |
'0' |
'84.50%%' |
'210' |
'0' |
'227' |
'0' |
'92.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'65.40%%' |
'0' |
'67.90%%' |
'108' |
'0' |
'124' |
'0' |
'87.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'75.80%%' |
'0' |
'77.20%%' |
'80' |
'0' |
'89' |
'0' |
'89.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'83.30%%' |
'0' |
'83.00%%' |
'58' |
'0' |
'63' |
'0' |
'92.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'94.40%%' |
'0' |
'88.00%%' |
'57' |
'0' |
'61' |
'0' |
'93.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Reported' |
'1.4551' |
'0' |
'1.254' |
'24' |
'0' |
'38.649' |
'0' |
'0.621' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'61.80%%' |
'0' |
'64.70%%' |
'379' |
'0' |
'504' |
'0' |
'75.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'61.50%%' |
'0' |
'64.30%%' |
'763' |
'0' |
'1019' |
'0' |
'74.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'39.80%%' |
'0' |
'44.80%%' |
'761' |
'0' |
'1392' |
'0' |
'54.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Reported' |
'98.10%%' |
'0' |
'90.00%%' |
'42' |
'0' |
'42' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Reported' |
'0.00%%' |
'0' |
'N/A' |
'0' |
'0' |
'0' |
'0' |
'0.00%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Reported' |
'0.00%%' |
'0' |
'N/A' |
'0' |
'0' |
'0' |
'0' |
'0.00%%' |
'0' |
'0' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-RU4' |
'? Adjusted Percentile' |
'Reported' |
'64' |
'0' |
'60.1' |
'N/A' |
'3' |
'N/A' |
'3' |
'24' |
'0' |
'N/A' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-RU4' |
'? Outlier Status' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'PY2' |
'DPH' |
'UC San Diego Medical Center' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'54.70%%' |
'0' |
'55.10%%' |
'388' |
'0' |
'666' |
'0' |
'58.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Reported' |
'65.70%%' |
'0' |
'65.90%%' |
'440' |
'0' |
'666' |
'0' |
'66.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'66.10%%' |
'0' |
'67.10%%' |
'486' |
'0' |
'666' |
'0' |
'73.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Reported' |
'52.20%%' |
'0' |
'55.60%%' |
'115' |
'0' |
'199' |
'0' |
'57.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'48.70%%' |
'0' |
'51.60%%' |
'323' |
'0' |
'326' |
'0' |
'99.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'60.20%%' |
'0' |
'63.20%%' |
'69' |
'0' |
'105' |
'0' |
'65.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Reported' |
'80.50%%' |
'0' |
'79.30%%' |
'188' |
'0' |
'224' |
'0' |
'83.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'89.50%%' |
'0' |
'89.50%%' |
'65' |
'0' |
'67' |
'0' |
'97.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'89.80%%' |
'0' |
'88.00%%' |
'156' |
'0' |
'158' |
'0' |
'98.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'70.50%%' |
'0' |
'72.40%%' |
'97' |
'0' |
'101' |
'0' |
'96.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'78.60%%' |
'0' |
'79.70%%' |
'82' |
'0' |
'82' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'82.50%%' |
'0' |
'82.60%%' |
'96' |
'0' |
'102' |
'0' |
'94.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'67.50%%' |
'0' |
'69.60%%' |
'89' |
'0' |
'89' |
'0' |
'100.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Reported' |
'0.8812' |
'0' |
'0.8469' |
'46' |
'0' |
'54.806' |
'0' |
'0.8393' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'64.90%%' |
'0' |
'67.40%%' |
'2266' |
'0' |
'2469' |
'0' |
'91.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'90.70%%' |
'0' |
'90.00%%' |
'2963' |
'0' |
'3010' |
'0' |
'98.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'1.60%%' |
'0' |
'25.00%%' |
'555' |
'0' |
'1280' |
'0' |
'43.40%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Reported' |
'84.20%%' |
'0' |
'84.80%%' |
'31' |
'0' |
'32' |
'0' |
'96.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Reported' |
'8.40%%' |
'0' |
'10.00%%' |
'0' |
'0' |
'150' |
'0' |
'0.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Reported' |
'42.90%%' |
'0' |
'50.00%%' |
'131' |
'0' |
'170' |
'0' |
'77.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'UC San Francisco Medical Center' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-PC1' |
'Comprehensive Diabetes Care: A1C Control (<8%%) (CDC-H8)' |
'Reported' |
'59.80%%' |
'0' |
'58.50%%' |
'1752' |
'0' |
'2770' |
'0' |
'63.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-PC2' |
'Comprehensive Diabetes Care: Eye Exam (CDC-E)' |
'Reported' |
'42.70%%' |
'0' |
'47.60%%' |
'1494' |
'0' |
'2770' |
'0' |
'53.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-PC3' |
'Comprehensive Diabetes Care: Blood Pressure Control (CDC-BP)' |
'Reported' |
'74.20%%' |
'0' |
'74.30%%' |
'2101' |
'0' |
'2770' |
'0' |
'75.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-PC4' |
'Asthma Medication Ratio (AMR)' |
'Reported' |
'50.30%%' |
'0' |
'55.60%%' |
'407' |
'0' |
'617' |
'0' |
'66.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-PC5' |
'Medication Reconciliation Post Discharge (MRP)' |
'Reported' |
'54.10%%' |
'0' |
'56.40%%' |
'940' |
'0' |
'1592' |
'0' |
'59.10%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-PC6' |
'7 Day Post-Discharge Follow-Up for High Risk Beneficiaries' |
'Reported' |
'47.20%%' |
'0' |
'51.50%%' |
'212' |
'0' |
'403' |
'0' |
'52.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-PC7' |
'Children and Adolescent Access to PCP (CAP)' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-PC7' |
'? 12-24 Months' |
'Reported' |
'93.80%%' |
'0' |
'94.20%%' |
'1436' |
'0' |
'1503' |
'0' |
'95.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-PC7' |
'? 25 Months-6 Years' |
'Reported' |
'84.50%%' |
'0' |
'85.30%%' |
'7243' |
'0' |
'8267' |
'0' |
'87.60%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-PC7' |
'? 7-11 Years' |
'Reported' |
'82.10%%' |
'0' |
'87.60%%' |
'7231' |
'0' |
'8016' |
'0' |
'90.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-PC7' |
'? 12-19 Years' |
'Reported' |
'78.60%%' |
'0' |
'85.70%%' |
'8785' |
'0' |
'10068' |
'0' |
'87.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-PC8' |
'Childhood Immunization Status (CIS) Combination 3' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-PC9' |
'Immunization for Adolescents (IMA) Combination 2' |
'Reported' |
'33.80%%' |
'0' |
'35.10%%' |
'406' |
'0' |
'1049' |
'0' |
'38.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-SC1' |
'Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy' |
'Reported' |
'75.30%%' |
'0' |
'76.70%%' |
'103' |
'0' |
'129' |
'0' |
'79.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-SC2' |
'Coronary Artery Disease (CAD): Antiplatelet Therapy' |
'Reported' |
'85.40%%' |
'0' |
'85.70%%' |
'425' |
'0' |
'476' |
'0' |
'89.30%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-SC3' |
'Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%%)' |
'Reported' |
'81.30%%' |
'0' |
'82.20%%' |
'213' |
'0' |
'249' |
'0' |
'85.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-SC4' |
'Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%%)' |
'Reported' |
'86.60%%' |
'0' |
'86.90%%' |
'61' |
'0' |
'67' |
'0' |
'91.00%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-SC5' |
'Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin-Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'89.20%%' |
'0' |
'83.00%%' |
'115' |
'0' |
'133' |
'0' |
'86.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-SC6' |
'Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction' |
'Reported' |
'91.80%%' |
'0' |
'88.00%%' |
'86' |
'0' |
'91' |
'0' |
'94.50%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-IP1' |
'Surgical Site Infection (SSI) (Reported as SIR)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-IP2' |
'Perioperative Care: Selection of Prophylactic Antibiotic - 1st OR 2nd Generation Cephalosporin' |
'Reported' |
'82.10%%' |
'0' |
'82.90%%' |
'913' |
'0' |
'1091' |
'0' |
'83.70%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-IP3' |
'Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis' |
'Reported' |
'95.30%%' |
'0' |
'90.00%%' |
'1030' |
'0' |
'1082' |
'0' |
'95.20%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-IP4' |
'Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections' |
'Reported' |
'0.00%%' |
'0' |
'25.00%%' |
'148' |
'0' |
'181' |
'0' |
'81.80%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-IP5' |
'Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-IP6' |
'Stroke: Discharged on Antithrombotic Therapy (TJC STK-2)' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-RU1' |
'Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients (QPP)' |
'Reported' |
'' |
'1' |
'10.00%%' |
'' |
'1' |
'125' |
'0' |
'' |
'1' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-RU2' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients 18 Years and Older' |
'Reported' |
'61.70%%' |
'0' |
'64.50%%' |
'99' |
'0' |
'134' |
'0' |
'73.90%%' |
'0' |
'1' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-RU3' |
'Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 to 17 years old' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-RU4' |
'Unplanned Reoperation within the 30 Day Postoperative Period (QPP)' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'0' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-RU4' |
'? Adjusted Percentile' |
'Reported' |
'39' |
'0' |
'37.6' |
'N/A' |
'3' |
'N/A' |
'3' |
'44' |
'0' |
'N/A' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-RU4' |
'? Outlier Status' |
'Reported' |
'N/A' |
'3' |
'N/A' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'3' |
'N/A' |
'PY2' |
'DPH' |
'Ventura County Medical Center' |
'Q-RU5' |
'Concurrent Use of Opioids and Benzodiazepines' |
'Not Reported' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |
'' |